RenovoRx has completed patient enrollment for its Phase 3 TIGeR-PaC study for locally advanced pancreatic cancer, a significant milestone for the company's lead drug-device combination. While this de-risks the trial's execution, the pivotal overall survival data is not expected until the second half of 2027, indicating a long wait for definitive results.
RenovoRx announced the completion of patient enrollment for its Phase 3 TIGeR-PaC study, a critical step in the development of its targeted pancreatic cancer therapy. This milestone confirms the trial is progressing as planned and reduces execution risk. However, the primary endpoint (overall survival) data is not anticipated until the second half of 2027, meaning a significant period of uncertainty remains for investors. The company's RenovoCath device is already commercialized, generating modest sales, but the IAG combination product is the major value driver. The long timeline for pivotal data means RNXT shares may trade sideways or be subject to broader market sentiment until closer to the data readout, with potential volatility around interim analyses or any news regarding the commercialization of RenovoCath.